Article · 28 Jun 2025
Short communicationPublished 26 Apr 2021
Cystatin C in patients with coronary artery disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Cystatin C, first and foremost known as a marker of renal function and considered a better marker of glomerular filtration rate (GFR) than serum creatinine, has been suggested as a possible independent biomarker of cardiovascular disease (CVD). The purpose of this study is toassess the relation between level of serum Cystatin C and severity of coronary artery disease (CAD) in patients without chronic kidney disease (CKD). Methodology & Theoretical Orientation: In this cross-sectional study, we included 80 patients with CAD divided in two groups (group I with acute coronary artery disease and group II with chronic stable coronary artery disease) 40 patients each and acquired their demographic characteristics, medical histories, and listings of the concurrent medications they were taking. All patients with CAD underwent ECG, echocardiography, coronary angiography, serum Cystatin C level, cardiac enzymes and other routine laboratory tests. Findings: As regard demographic data and comorbidities there was no significant difference between the two groups as regard gender, diabetes mellitus, hypertension or smoking. Also, As regard level of serum Cystatin C, the mean and SD in 1 vessel affection was 0.92±0.07 while in 2 vessels affection was 1.07±0.13 and 3 vessels affection was 1.41±0.05 with (P< 0.01). Finally, there was a highly significant difference as regard Cystatin C level with mean and SD 1.21±0.18 in ST-segment elevation MI while mean and SD was 0.96±0.09 in Non ST-segment MI or unstable angina with (P< 0.01). There was a statistically significant correlation between level of Cystatin C and severity of CAD (p < 0.05) Conclusions and Significance: Serum cystatin C has a significant effect on the severity of coronary artery disease (CAD) , being higher in patients with 3 vessels disease and severe CAD.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cardiovascular Pharmacology: Open Access.
Article · 28 Jun 2025
Beta Blockers and Their Expanding Role in Cardiovascular Disease
Article · 28 Jun 2025
Emerging Role of PCSK9 Inhibitors in Lipid Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCardiovascular Pharmacology: Open Access
- SubjectPharmaceutical Sciences
- SubjectCardiology
- BylineArticles whose byline prints “Mohamed Wasfy Mohamed”
